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Kang and coll.1 reported the data from a large prospective
cohort of patients with Staphylococcus aureus infection. The
authors found that Methicillin resistant S. aureus (MRSA) ac-
counted for 57.8% of 4949 cases observed and reported a close
relationship between an inappropriate antimicrobial therapy
and mortality. However, the study was not tailored to find
data about the impact of antimicrobial therapy on outcome
of bone and joint infection and no data was provided about
the efficacy of the newer antibiotics currently employed for
the treatment of osteomyelitis sustained by MRSA.
In an observational study, we considered the cases of
osteomyelitis referred to our ward during a 3-year period
and evaluated the efficacy of the IV agents commonly used
in our hospital (linezolid, daptomycin and teicoplanin) for
the treatment of osteomyelitis sustained by MRSA.
Osteomyelitis was defined by: (i) persistent bone pain,
erythema or tenderness, (ii) positive cultures from bone
biopsy, or from soft tissue biopsy, or from swabs obtained
from surgical wounds, or from pus aspirated from soft tissue
surrounding the infected bone, (iii) radiographic findings, or
operative findings suggestive of infection.2
The inclusion criteria were: (i) positive cultures for MRSA
from 3 specimens obtained by bone or soft tissue biopsy or
by swabs from surgical wounds or pus aspirated from
surrounding soft tissue3; (ii) S. aureus susceptibility as-
sessed by E-test; (iii) age > 18 years. The exclusion criteria
were: (i) co-infection with HIV; (ii) evidence of metastatic
infection or polymicrobic infection; (iii) previous treatment
with the investigated drugs.
Study drugs were administered following standardised pro-
tocols: teicoplanin 7 mg  kg of body weight IV once daily or
14 mg kg every other day (drug was started daily and switch
on the every other day schedule was allowed after 2 weeks of
treatment were completed),4 linezolid 600 mg every 12 h IV
during the first 2 weeks, followed by oral or IV administration
onphysician’s judgment,daptomycin8mgkgofbodyweight
intravenously once daily. The length of each treatment was
left to the discretion of the treating physician and the efficacy
was evaluated by intention to treat analysis. Cure was defined
by clinical, laboratory and radiologic findings.20163-4453/$36 ª 2011 The British Infection Association. Published by E
doi:10.1016/j.jinf.2011.04.015One-hundred-fifty-six patients with chronic osteomyeli-
tis were observed, 54 (35%) fulfilled inclusion criteria
(median age 58 years [interquartile range 25e66], male:fe-
male ratio 1.9:1) (Table 1). Forty-two (78%) reported previ-
ous unsuccessful antibiotic treatment and 10 (19%)
reported to be affected with chronic diseases. Fracture
fixators were present in 11 (20%) cases. C reactive protein
(CRP) was elevated in all cases, blood leukocytes were
above 10000 cells/mL in 20 (37%) cases. Twenty-nine
patients received teicoplanin, 13 linezolid, and 12 dapto-
mycin. Median (IQR) length of antibiotic treatment
was 16 (14e20) weeks for cases treated with teicoplanin,
12 (8e12) weeks for cases treated with linezolid, and
11 (6e12) weeks for cases treated with daptomycin.
Fig. 1 reports the time to normalization of CRP. Median
time to CRP normalization was 7 weeks for daptomycin,
8 weeks for linezolid, and 12 weeks for teicoplanin
(X2 Z 14.1; p < 0.001). Moderate or severe side effects
were reported in 4 patients, 3 on linezolid treatment (2
cases had optic neuritis, 1 anaemia), and 1 on Daptomycin
treatment (transient increase of Creatin-Kinase), drug had
to be withdrawn in all cases reporting side effects after
linezolid treatment. Cure rate (intention to treat analysis)
was 83% for the cases receiving teicoplanin, 77% for those
receiving linezolid and 92% for those receiving daptomycin.
Three cases with MIC to teicoplanin  4 mg/ml failed.
Osteomyelitis managementmay be favourably influenced
by an efficacious antibiotic treatment. In this study, a high
cure rate was obtained with all the drugs investigated, and
responders could reduce the time of disability avoiding
further surgical procedures and expensive treatments.
Glycopeptides have largely proven their efficacy against
MRSA, but their failure rate increases with the MIC for
vancomycin.5 Patients on teicoplanin treatment reported
a cure rate comparable to the other drugs investigated, but
CRPnormalizationoccurred after longer timeand relapses oc-
curred inthreecasesafter teicoplaninwaswithdrawn,despite
the drug had to be administered for a long period.4,6e8 Of
note, our cases with S. aureus MIC to teicoplanin close to
the higher range of susceptibility had the higher failure rate.
Linezolid may concentrate within the bone and is avail-
able in both IV and oral formulations, giving the advantage
of balancing the acquisition costs by the reduction of the
periods of hospitalization and IV administration of the drug.
In our experience, the response rate was 100% for the cases
tolerating linezolid, but it was reduced to 77% in thelsevier Ltd. All rights reserved.
Table 1 Main findings, cure rate and approximate cost of the treatment received.
Findings Teicoplanin (29 cases) Linezolid (13 cases) Daptomycin (12 Cases)
Age [yrs, median (IQR)] 59 (25e66) 58 (26e65) 53 (32e64)
% males 65 69 64
Associate conditionsa (%) 11 (38) 4 (31) 6 (50)
Time to diagnosis [months, median (IQR)] 8 (5e10) 9 (4e9) 9 (8e12)
Cases (%) with previous ineffective antibiotic treatment 23 (79) 10 (77) 9 (75)
Median treatment period (weeks) 16 12 11
Cure rate (%) 83 77 92
Cost for unit (V) 28b 55c 93d
Daily cost (V)e 69 110 104
Total acquisition cost for the treatment period (V)f 7728 9240 8008
a Associate conditions are considered underlying diseases or the presence of fracture fixators.
b Vials containing 200 mg of teicoplanin.
c Sacs or pills containing 600 mg of linezolid.
d Vials containing 500 mg of daptomycin.
e Daily cost was calculated assuming a mean body weight of 70 kg.
f Total cost was calculated multiplying each drug median treatment period by the daily cost.
Letter to the Editor 103intention to treat analysis, because the side effects lead to
the drug withdrawal in 3 cases before a complete cure was
obtained. Similar concerns about linezolid toxicity were
reported by other authors when the drug was administered
for long time and linezolid is currently scheduled only for
a 28-day treatment period.9e11
A number of studies have shown the effectiveness of
daptomycin in the treatment of osteomyelitis.12,13 In our
experience, daptomycin provided an elevated cure rate
and the reduction of the treatment period, highlighted by
faster normalization of PCR and by the absence of relapses
occurring after the drug was withdrawn. Moreover, fracture
fixators were present in 4 cases on daptomycin treatment
and cure was reported in 3 of these cases, probably, be-
cause of the drug efficacy on biofilm forming bacteria.14
As the acquisition cost is a major problem related to the
current IV drugs active against MRSA, we evaluated the
approximate drug cost (Table). In this analysis, the higher
acquisition cost of linezolid and daptomycin was balanced
by the reduction of the treatment period.
In conclusion, antibiotic treatment is a valuable option
for osteomyelitis by MRSA. Daptomycin and linezolid have
to be considered at least equivalent to teicoplanin for theFigure 1 KaplaneMeier estimate of the time to CRP normal-
ization in relation to treatment.treatment of MRSA osteomyelitis and the role of each drug
has to be evaluated on the basis of many considerations
regarding each drug cost, toxicity and acceptability.
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